Abcellera Biologics Inc (ABCL)

$3.73 +0.09 (2.47%)
Market Cap 1.12B
Revenue (ttm) 28.83M
Net Income (ttm) -162.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -564.90%
Debt to Equity Ratio 0.00
Volume 4,427,900
Avg Vol 5,553,922
Day's Range N/A - N/A
Shares Out 299.34M
Stochastic %K 80%
Beta 0.70
Analysts Strong Sell
Price Target $9.00

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 West 4th Ave, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Nov. 30 at 8:51 PM
$ABCL $ABCL TIGHT!
0 · Reply
snowPOW
snowPOW Nov. 30 at 7:03 PM
$ABCL Target development company in New Brunswick taken for 3B Yet AbCellera is still just called at 1B? https://www.wsj.com/business/deals/johnson-johnson-to-buy-halda-therapeutics-for-3-05-billion-2e460ca1?mod=tech_feat3_biotech_pos1
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 30 at 6:21 AM
$ABCL $ABCL 's CEO understands the mission. Think different, say no to low ROIC and undifferentiated projects, maintain a healthy balance sheet, & have a plan to solve a difficult global problem. If AbCellera succeeds, it becomes a meaningful step toward Canada’s technological sovereignty.
1 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 29 at 11:14 PM
$ABCL $ABCL now needs to hold above the 200-day MA. Wave 3 target $10.
0 · Reply
PolycarpFX
PolycarpFX Nov. 29 at 7:37 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 29 at 1:43 AM
$ABCL $ABCL We have now reached the 0.618 Fib of wave 2, and we are sitting simultaneously on a support level, plus we have contact with the 200 SMA daily (blue line). These are extremely bullish signals for this chart. Our current chart picture is so strong that one can consider it a good bottom. I suspect from here an upward movement toward wave 3 at $10. I'm bullish on $ABCL.
2 · Reply
BstnGeorge
BstnGeorge Nov. 28 at 8:32 PM
$ABCL
1 · Reply
Samb2344
Samb2344 Nov. 28 at 5:19 PM
$ABCL back to $4S soon
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 28 at 4:41 PM
$ABCL LOL
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 28 at 4:38 PM
$ABCL READ...
0 · Reply
Latest News on ABCL
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 12:23 AM EST - 8 days ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 20 days ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 7:16 PM EST - 23 days ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 24 days ago

AbCellera Reports Q3 2025 Business Results

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 7, 2025, 4:05 PM EDT - 7 weeks ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera Biologics: Entering Growth Phase After A Pause

Oct 6, 2025, 7:35 AM EDT - 7 weeks ago

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 29, 2025, 4:05 PM EDT - 2 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 2 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 3 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:48 PM EDT - 4 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 7, 2025, 4:05 PM EDT - 4 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Jun 2, 2025, 6:45 PM EDT - 6 months ago

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 30, 2025, 1:00 PM EDT - 6 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 14, 2025, 5:00 PM EDT - 7 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 12, 2025, 3:30 PM EDT - 7 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 9, 2025, 7:30 PM EDT - 7 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:33 PM EDT - 7 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 7 months ago

AbCellera Reports Q1 2025 Business Results

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 3:00 PM EDT - 7 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 3, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 25, 2025, 4:30 PM EDT - 8 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:26 PM EST - 9 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Full Year 2024 Business Results

AbCellera to Participate at Upcoming Investor Conferences in March

Feb 11, 2025, 4:05 PM EST - 10 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 21, 2025, 4:05 PM EST - 11 months ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Jan 13, 2025, 9:00 AM EST - 11 months ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera Biologics: Still A Concept Stock

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera: A Platform To Pipeline Transition

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Present at Upcoming Investor Conferences in September

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

AbCellera: A Waiting Game With High Uncertainty

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Jul 21, 2024, 5:37 AM EDT - 1 year ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

FATE

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Jun 13, 2024, 5:40 AM EDT - 1 year ago

Down 57%, Is AbCellera Biologics a Buy on the Dip?

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1, 2024, 9:00 AM EDT - 1 year ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Stocktradesmoon
Stocktradesmoon Nov. 30 at 8:51 PM
$ABCL $ABCL TIGHT!
0 · Reply
snowPOW
snowPOW Nov. 30 at 7:03 PM
$ABCL Target development company in New Brunswick taken for 3B Yet AbCellera is still just called at 1B? https://www.wsj.com/business/deals/johnson-johnson-to-buy-halda-therapeutics-for-3-05-billion-2e460ca1?mod=tech_feat3_biotech_pos1
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 30 at 6:21 AM
$ABCL $ABCL 's CEO understands the mission. Think different, say no to low ROIC and undifferentiated projects, maintain a healthy balance sheet, & have a plan to solve a difficult global problem. If AbCellera succeeds, it becomes a meaningful step toward Canada’s technological sovereignty.
1 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 29 at 11:14 PM
$ABCL $ABCL now needs to hold above the 200-day MA. Wave 3 target $10.
0 · Reply
PolycarpFX
PolycarpFX Nov. 29 at 7:37 PM
$ABCL
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 29 at 1:43 AM
$ABCL $ABCL We have now reached the 0.618 Fib of wave 2, and we are sitting simultaneously on a support level, plus we have contact with the 200 SMA daily (blue line). These are extremely bullish signals for this chart. Our current chart picture is so strong that one can consider it a good bottom. I suspect from here an upward movement toward wave 3 at $10. I'm bullish on $ABCL.
2 · Reply
BstnGeorge
BstnGeorge Nov. 28 at 8:32 PM
$ABCL
1 · Reply
Samb2344
Samb2344 Nov. 28 at 5:19 PM
$ABCL back to $4S soon
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 28 at 4:41 PM
$ABCL LOL
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 28 at 4:38 PM
$ABCL READ...
0 · Reply
Ed_Ng
Ed_Ng Nov. 28 at 3:51 PM
$ABCL
1 · Reply
sogenerous
sogenerous Nov. 28 at 3:50 PM
$ABCL 50K share insider buy, decent support area 3.5-3.7s needs > 4 to confirm
1 · Reply
Ed_Ng
Ed_Ng Nov. 28 at 3:30 PM
$ABCL when I market turns red, this will drop real hard. Be prepared!
1 · Reply
GoImugene
GoImugene Nov. 28 at 1:15 PM
$ABCL Stock looks like it has a good entry here. MACD bullish cross
1 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 28 at 5:44 AM
$ABCL $ABCL - near/at the 200DMA - MACD starting to recover - insider buying alert this week 🚨 - beautiful turnaround at the lower line of the (intact) uptrend - defended the 0.618Fib level Nice pumping in overnight trading to $3.90 (+7%) … Time to enter NOW if you‘re not already invested
1 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 28 at 2:23 AM
$ABCL I think $33.00 is on the low end there bud 😉👀will probably get there much sooner than everyone thinks 😉
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 27 at 9:32 PM
$ABCL LOOK AT THE CHARTS...
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 27 at 9:28 PM
$ABCL FOLLOW
0 · Reply
estatebuyersmia
estatebuyersmia Nov. 27 at 9:25 PM
$ABCL WE ARE IN FOR A POWERFUL UPTURN, FASTEN YOUR SEAT BELTS...
1 · Reply
estatebuyersmia
estatebuyersmia Nov. 27 at 9:23 PM
$ABCL INTERESTING...
0 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 27 at 3:31 PM
$ABCL $ABCL flips the Monthly 20 MA from resistance to support for the first time in 3 years
1 · Reply
Stocktradesmoon
Stocktradesmoon Nov. 27 at 2:55 AM
$ABCL All price action we don’t like is manipulation
0 · Reply